# Lexicon Fundamentals

LXRX | Stock | ## USD 2.13 0.09 4.05% |

Lexicon Pharmaceutcl fundamentals help investors to digest information that contributes to Lexicon Pharmaceutcl's financial success or failures. It also enables traders to predict the movement of Lexicon Stock. The fundamental analysis module provides a way to measure Lexicon Pharmaceutcl's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexicon Pharmaceutcl stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Lexicon | Select Account or Indicator |

**M**in 2022, whereas Consolidated Income is likely to drop (94.7

**M**) in 2022.

## Lexicon Price to Book Analysis

Lexicon Pharmaceutcl's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. 2019 | 2021 | 2022 (projected) | |

Receivables | 56.53 M | 14 K | 14.37 K |

Inventories | 4.24 M | 3.82 M | 3.54 M |

P/B | = | MV Per Share BV Per Share |

## Current Lexicon Pharmaceutcl Price to Book | 2.87 X |

Most of Lexicon Pharmaceutcl's fundamental indicators, such as Price to Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexicon Pharmaceutcl is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Lexicon Price to Book Historical Pattern

Today, most investors in Lexicon Pharmaceutcl Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lexicon Pharmaceutcl's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to book growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lexicon Pharmaceutcl price to book as a starting point in their analysis.

Lexicon Pharmaceutcl Price to Book |

Share

Timeline |

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Compare to competition |

## Lexicon Book Value per Share

## Book Value per Share | ## 0.8 |

Based on the latest financial disclosure, the price to book indicator of Lexicon Pharmaceutcl is roughly 2.87 times. This is 88.82% lower than that of the Healthcare sector and 52.48% lower than that of the Biotechnology industry. The price to book for all United States stocks is 69.82% higher than that of the company.

## Lexicon Pharmaceutcl Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lexicon Pharmaceutcl's current stock value. Our valuation model uses many indicators to compare Lexicon Pharmaceutcl value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lexicon Pharmaceutcl competition to find correlations between indicators driving Lexicon Pharmaceutcl's intrinsic value. More Info.Lexicon Pharmaceutcl is rated**third**overall in cash per share category among related companies. It is rated

**third**overall in return on asset category among related companies . Average Assets is likely to rise to about 234.9

**M**in 2022. Tangible Asset Value is likely to rise to about 94.8

**M**in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lexicon Pharmaceutcl by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lexicon Pharmaceutcl's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexicon Pharmaceutcl's earnings, one of the primary drivers of an investment's value.

## Lexicon Cash per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexicon Pharmaceutcl's direct or indirect competition against its Cash per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexicon Pharmaceutcl could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceutcl by comparing valuation metrics of similar companies.Lexicon Pharmaceutcl is currently under evaluation in cash per share category among related companies.

## Lexicon Pharmaceutcl Current Valuation Drivers

We derive many important indicators used in calculating different scores of Lexicon Pharmaceutcl from analyzing Lexicon Pharmaceutcl's financial statements. These drivers represent accounts that assess Lexicon Pharmaceutcl's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lexicon Pharmaceutcl's important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (741.67 K) | (596.77 K) | 707.25 K | (748.9 K) | (1.01 M) | (1.09 M) | |

Revenue Per Employee | 519.17 K | 312.92 K | 1.75 M | 306.79 K | 3.42 K | 3.52 K | |

Average Assets | 381.45 M | 328.52 M | 338.49 M | 268.96 M | 168.54 M | 234.91 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (132.68 M) | (98.26 M) | 146.56 M | (42.85 M) | (86.74 M) | (93.59 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (125.27 M) | (96.09 M) | 148.45 M | (41.1 M) | (86.66 M) | (93.51 M) | |

Earnings before Tax | (135.65 M) | (120.55 M) | 124.12 M | (58.57 M) | (87.76 M) | (94.69 M) | |

Average Equity | 96.89 M | (8.67 M) | 42.81 M | 72.03 M | 134.99 M | 133.1 M | |

Enterprise Value | 1.06 B | 899.39 M | 515.95 M | 369.83 M | 506.22 M | 619.8 M | |

Free Cash Flow | (185.62 M) | (148.7 M) | 113.74 M | (132.04 M) | (88.24 M) | (95.2 M) | |

Invested Capital | 418.63 M | 317.34 M | 497.19 M | (2.18 M) | 6.18 M | 6.34 M | |

Invested Capital Average | 250.56 M | 365.38 M | 398.34 M | 189.34 M | 14.78 M | 15.17 M | |

Market Capitalization | 1.04 B | 703.34 M | 441.03 M | 401.76 M | 586.65 M | 651.51 M | |

Tangible Asset Value | 340.11 M | 189.47 M | 353.46 M | 159.25 M | 92.37 M | 94.8 M | |

Working Capital | 216.51 M | 136.57 M | 272.41 M | 110.91 M | 66.8 M | 68.55 M |

## Lexicon Fundamentals

Return On Equity | (69.18) % | |||

Return On Asset | (32.90) % | |||

Current Valuation | 313.4 M | |||

Shares Outstanding | 188.73 M | |||

Shares Owned by Insiders | 1.00 % | |||

Shares Owned by Institutions | 82.27 % | |||

Number of Shares Shorted | 4.26 M | |||

Price to Earning | 21.02 X | |||

Price to Book | 2.87 X | |||

Revenue | 125 K | |||

Gross Profit | (54.75 M) | |||

EBITDA | (95.38 M) | |||

Net Income | (97.06 M) | |||

Cash and Equivalents | 136.2 M | |||

Cash per Share | 0.72 X | |||

Total Debt | 30.63 M | |||

Debt to Equity | 0.21 % | |||

Current Ratio | 7.54 X | |||

Book Value Per Share | 0.76 X | |||

Cash Flow from Operations | (90.11 M) | |||

Short Ratio | 8.40 X | |||

Earnings Per Share | (0.61) X | |||

Price to Earnings To Growth | (0.07) X | |||

Number of Employees | 87 | |||

Beta | 1.36 | |||

Market Capitalization | 413.31 M | |||

Total Asset | 284.2 M | |||

Retained Earnings | (1.45 B) | |||

Working Capital | 139.74 M | |||

Current Asset | 171.5 M | |||

Current Liabilities | 31.77 M | |||

Z Score | 0.8 |

## About Lexicon Pharmaceutcl Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lexicon Pharmaceutcl's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceutcl using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceutcl based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | ||

Deferred Revenue | 29.9 M | 30.7 M | |

Cost of Revenue | 2.2 M | 2.5 M | |

Revenues | 298 K | 305.8 K | |

Revenue to Assets | 0.002177 | 0.002234 | |

Revenue Per Employee | 3.4 K | 3.5 K |

## Be your own money manager

Our tools can tell you how much better you can do entering a position in Lexicon Pharmaceutcl without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Options Analysis Now

## Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |

All Next | Launch Module |

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lexicon Pharmaceutcl using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Additionally, see Lexicon Pharmaceutcl Piotroski F Score and Lexicon Pharmaceutcl Altman Z Score analysis. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

## Complementary Tools for analysis

When running Lexicon Pharmaceutcl price analysis, check to measure Lexicon Pharmaceutcl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceutcl is operating at the current time. Most of Lexicon Pharmaceutcl's value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceutcl's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lexicon Pharmaceutcl's price. Additionally, you may evaluate how the addition of Lexicon Pharmaceutcl to your portfolios can decrease your overall portfolio volatility.

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Equity ValuationCheck real value of public entities based on technical and fundamental data | Go | |

Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk | Go | |

Content SyndicationQuickly integrate customizable finance content to your own investment portal | Go | |

Insider ScreenerFind insiders across different sectors to evaluate their impact on performance | Go | |

Analyst RecommendationsAnalyst recommendations and target price estimates broken down by several categories | Go | |

Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | Go | |

Bond DirectoryFind actively traded corporate debentures issued by US companies | Go | |

Insider ScreenerFind insiders across different sectors to evaluate their impact on performance | Go | |

Insider ScreenerFind insiders across different sectors to evaluate their impact on performance | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go |

Is Lexicon Pharmaceutcl's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceutcl. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceutcl listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth YOY (0.63) | Market Capitalization 402 M | Quarterly Revenue Growth YOY 0.7 | Return On Assets (0.33) | Return On Equity (0.69) |

The market value of Lexicon Pharmaceutcl is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceutcl's value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceutcl's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceutcl's market value can be influenced by many factors that don't directly affect Lexicon Pharmaceutcl's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lexicon Pharmaceutcl's value and its price as these two are different measures arrived at by different means. Investors typically determine Lexicon Pharmaceutcl value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceutcl's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.